



One Luitpold Drive, PO Box 9001, Shirley, New York 11967
 (631) 924-4000 • (800) 645-1706 • Fax (631) 924-1731

PRESS RELEASE

FOR IMMEDIATE RELEASE

June 16, 2010

Contact:

American Regent, Inc.
 Walter Tozzi, R.Ph., M.S., M.B.A.
 Sr. Director of Marketing and Professional Services
 631-924-4000
 wtozzi@americanregent.com

**American Regent announces the availability of
 Methylergonovine Maleate Injection, USP**

Shirley, NY – (June 16, 2010): American Regent, Inc. purchased PharmaForce Inc. (Columbus, OH) on December 29, 2009 and is pleased to announce that Methylergonovine Maleate Injection, USP is now available under the American Regent label with a new NDC.

It is “AP” rated to Methergine® (Novartis). It is Latex and Preservative Free.

Product	Strength	NDC Number	Shelf Pack
Methylergonovine Maleate Injection, USP	0.2 mg/mL, 1 mL Single Dose Vial	0517-0740-20 Previous NDC: 40042-051-01	20

Headquartered in Shirley, NY, American Regent, Inc., distributes over 80 pharmaceutical products under the PharmaForce or their own label, including Venofer (iron sucrose injection, USP) the #1 selling IV iron therapy in the U.S. For more information about this product or other American Regent or PharmaForce products, please contact our customer service department at 1-800-645-1706.

Source: American Regent, Inc.

See accompanying Full Prescribing Information

IMPORTANT SAFETY INFORMATION

Methylergonovine maleate injection, USP, is contraindicated in patients with hypertension; toxemia; pregnancy; and hypersensitivity.

Methylergonovine maleate should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V. administration is considered essential as a lifesaving measure, methylergonovine maleate injection should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided. Potent CYP 3A4 inhibitors should not be coadministered with methylergonovine.

Caution should be exercised in the presence of sepsis, obliterative vascular disease, hepatic or renal involvement. Also use with caution during the second stage of labor and when methylergonovine maleate is used concurrently with other vasoconstrictors or ergot alkaloids.

The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension has also been reported.